Examkin

Soru

Zorluk: Çok zorBipolar and Related Disorders

A 34-year-old woman is admitted to the inpatient psychiatric unit due to a 4-week history of severe depressed mood, hypersomnia, profound fatigue, and passive suicidal ideation. Her psychiatric history is significant for a severe manic episode at age 26 that required a 2-week hospitalization, establishing a diagnosis of bipolar I disorder. She discontinued her prescribed maintenance lithium two years ago due to weight gain. For the past month, she has been taking daily over-the-counter St. John's wort and 5-hydroxytryptophan (5-HTP) supplements. Her past medical history includes a non-functioning pituitary microadenoma diagnosed incidentally last year, for which she currently takes no medications.

Physical examination reveals a flat affect, psychomotor retardation, and delayed deep tendon reflexes.

Laboratory studies show:

Laboratory TestPatient ValueReference Range
Thyroid-stimulating hormone (TSH)1.5 µU/mL0.5–5.0 µU/mL
Free thyroxine (T4)0.5 ng/dL0.9–1.7 ng/dL

Comprehensive metabolic panel and complete blood count are within normal limits.

Which of the following are appropriate management steps for this patient? (Select all that apply)

  1. Initiate lurasidone and monitor for symptomatic improvementCevap
  2. Discontinue her current over-the-counter supplementsCevap
  3. C
    Initiate sertraline to target her current depressive episode
  4. D
    Initiate phenelzine to address her severe vegetative symptoms
  5. E
    Diagnose primary hypothyroidism and initiate levothyroxine therapy

Cevap

The appropriate management steps are to initiate an evidence-based treatment for bipolar depression, such as lurasidone, and to discontinue her serotonergic over-the-counter supplements.
The patient is experiencing an acute depressive episode in the context of Bipolar I disorder. Lurasidone is an FDA-approved, first-line atypical antipsychotic for the treatment of bipolar depression that carries a lower risk of metabolic side effects and is highly appropriate for this episode. Furthermore, the patient is taking St. John's wort and 5-HTP, both of which increase serotonergic tone. These over-the-counter supplements must be discontinued immediately because they lack robust efficacy for bipolar depression and pose a severe risk for serotonin syndrome if combined with prescribed psychiatric medications.

Adım Adım Çözüm

1
Identify the primary psychiatric diagnosis and phase of illness.
The patient has a history of a severe manic episode and is currently presenting with major depressive symptoms, confirming an acute depressive episode of Bipolar I disorder.
Accurate diagnosis of the mood episode dictates the appropriate psychopharmacological intervention and prevents treatments that could induce mood destabilization.
2
Evaluate the patient's current medication and supplement list for potential interactions.
The patient is taking St. John's wort and 5-HTP, both of which are strongly serotonergic.
Identifying concurrent serotonergic agents is critical to avoid precipitating serotonin syndrome when initiating new psychotropics.
3
Interpret the thyroid function tests in the context of her medical history.
The patient has a low free T4 with an inappropriately normal TSH, consistent with central (secondary) hypothyroidism, likely secondary to her known pituitary microadenoma.
Distinguishing between primary and secondary hypothyroidism is crucial, as secondary hypothyroidism requires evaluation of the adrenal axis before initiating thyroid hormone replacement to avoid an adrenal crisis.
4
Select the appropriate pharmacological interventions based on the gathered data.
Lurasidone is selected as a safe, first-line agent for bipolar depression, while the OTC supplements must be discontinued. SSRIs and MAOIs are contraindicated, and levothyroxine should be deferred pending adrenal evaluation.
This multimodal approach ensures effective treatment of bipolar depression while mitigating the risks of manic switch, drug interactions, and endocrine emergencies.

Anahtar Kavram

Management of acute bipolar I depression requires selecting approved mood stabilizers or atypical antipsychotics (e.g., lurasidone) while avoiding antidepressant monotherapy. Additionally, clinicians must remain vigilant for dangerous drug interactions (e.g., serotonin syndrome) and correctly interpret lab anomalies to rule out medical mimics or comorbidities.
Tahmini Süre:2m 30s
Bu soruyu puanla

Konular

Bipolar and Related Disorders

Bu konudan daha fazla soru